BioCentury
ARTICLE | Politics & Policy

FDA panels to discuss two more pain products

March 17, 2016 1:04 AM UTC

FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees will meet in June to discuss pain candidates CEP-33237 from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and ALO-02 from Pfizer Inc. (NYSE:PFE).

On June 7, the committees will discuss an NDA for CEP-33237 to treat pain severe enough to require a continuous, around-the-clock opioid analgesic when alternatives are inadequate. The twice-daily, acetaminophen-free hydrocodone bitartrate extended-release (ER) tablets are formulated with an abuse-deterrent technology. ...